ISCT 2023 All Sessions
ISCT 2023 All Sessions
Advanced Search This List
-
Contains 3 Component(s)
To launch the ISCT 2023 Paris Translational Pathway Program, ISCT President Jacques Galipeau is excited to present La Présidentielle, a deep dive into The Future of Immune Effector Cell Therapies for Cancer, featuring Society leaders at the very forefront of the cancer immunotherapy field. This opening session will explore the state of the art in chimeric antigen receptor (CAR) based therapies and other novel technologies for liquid and solid cancers and address persistent and emerging barriers to the successful adoption of these advanced therapies globally.
ISCT 2023 Presidential Plenary: LA PRÉSIDENTIELLE – A DEEP DIVE INTO THE FUTURE OF IMMUNE EFFECTOR CELL THERAPIES FOR CANCER
Chairs:
- Jacques Galipeau, MD, FRCP (C), University of Wisconsin- Madison, US
Speakers:
- Bruce Levine, PhD, University of Pennsylvania, US (Recording not available)
- Anna Sureda, MD, PhD, Institut Català d’Oncologia - Hospital Duran i Reynals (Barcelona), ES (Recording and slides not available)
- Mark Lowdell, PhD, FRCPath, FRSB, InmuneBio Inc., UK
-
Contains 2 Component(s)
Mitochondrial transfer is a relatively new technology mimicking a natural phenomenon through which cells replace the exhausted organelles with new, viable ones obtained from the environment. As pathological conditions are characterized also by mitochondrial dysfunction, the transfer (or transplantation) of new viable mitochondria to damaged cells, tissues or organs has shown promise to become an alternative treatment strategy to restore physiology. This session will present recent progress achieved in the field.
Science and Innovation Concurrent: THE RISE OF MITOCHONDRIAL TRANSFER TECHNOLOGY IN REGENERATIVE MEDICINE
Chairs:
- Rachele Ciccocioppo, MD, AOUI Policlinico GB Rossi & University of Verona, IT
Speakers:
- Mitochondrial Medicine: State of the art and perspective (Recording and slides not available)
Marvin Edeas, MD, PhD, Université de Paris, Institut Cochin, INSERM U1016, FR
- Mitochondrial transfer applications in organ transplantation
Giuseppe Orlando, MD, PhD, Marie Curie Fellow, Wake Forest School of Medicine, US
-
Contains 6 Component(s)
Cell and gene therapies represent a significant achievement, not only for the biotech and life sciences industry but also, and importantly, for patients who have witnessed the lifesaving potential of these new biotherapeutics. The progress for patients could not have been realized without the development of new technologies and this session brings together global experts to discuss the innovations that will shape the future of the field.
Science and Innovation Concurrent: IMPLEMENTING NEW TECHNOLOGIES IN CGT
Chairs:
- Rachele Ciccocioppo, MD, AOUI Policlinico GB Rossi & University of Verona, IT
- Giuseppe Orlando, MD, PhD, Marie Curie Fellow, Wake Forest School of Medicine, US
Speakers:
- The Future of Regulatory T Cell Therapy: Promises and Challenges
Maria Grazia Roncarolo, MD, Stanford University School of Medicine, US
- Bioengineering human organs: Getting to the heart of the matter
Doris Taylor, PhD, FACC, FAHA, Organamet Bio, US
- In vivo engineering of CAR T cells to treat heart disease
Haig Aghajanian, PhD, Capstan Therapeutics, US
-
Contains 6 Component(s)
Nanovesicular therapeutics (NVTs) are expected to have entirely novel properties in targeted drug delivery, providing a promising therapeutic platform for diseases with previously untreatable molecular targets or high unmet clinical need. Various concepts and technologies have been developed, such as the use of externally loaded nanovesicles or naturally secreted extracellular vesicles from unmodified or genetically modified cells from different starting materials. Artificially formed nanovesicular structures generated by serial extrusion techniques from living cells or hybrid constructs derived from a combination of synthetic and biological materials are increasingly being investigated. Few clinical trials have been conducted to date, and proof of efficacy in pivotal studies is still pending, yet expectations are high. This session is devoted to the technological considerations of NVT and the associated therapeutic prospects.
Science and Innovation Concurrent: PROMISE AND OBSTACLES OF CELL-DERIVED NANOVESICULAR THERAPEUTICS
Chairs:
- Eva Rohde, MD, Paracelsus Medical University Salzburg, AT
Speakers:
- Pluripotent stem cells as a source of extracellular vesicles for tissue repair – the other face of iPSCs
Ewa K. Zuba-Surma, PhD, DSc, Jagiellonian University in Krakow, PL
- Extracellular vesicle-based hybrid nanoparticles for therapeutic RNA delivery
Pieter Vader, PhD, University Medical Center Utrecht, NL
- Stromal cell-derived EVs and CDVs: Nanovesicle therapeutics and drug delivery systems
Mario Gimona, PhD, Paracelsus Medical University Salzburg, AT
-
Contains 4 Component(s)
The use of biomaterials has long been envisioned to enhance the therapeutic performance of cellular therapies. The session will highlight opportunities of novel 3D cell culture concepts and technologies towards innovative combined advanced therapy medicinal products.
Science and Innovation Concurrent: SCAFFOLDING AND EXTRACELLULAR MATRIX
Chairs:
- Giuseppe Orlando, MD, PhD, Marie Curie Fellow, Wake Forest School of Medicine, US
Speakers:
- Hurdles in 3D regeneration with multiple cell types (Recording and slides are not available)
Graziella Pellegrini, PhD, Università degli Studi di Modena e Reggio Emilia, IT
- 3D Bioprinting and Light-based Biofabrication in tissue engineering
Riccardo Levato, PhD, Utrecht University, NL
- Cell-based engineering of extracellular matrices designed to activate tissue regeneration
Ivan Martin, PhD, University of Basel, CH
-
Contains 2 Component(s)
This session will focus on discussing approaches to develop novel nucleases, base and prime editors as well as approaches to detect off target activities of the CRISPR/Cas and related nuclease. Speakers will focus on some of the clinical applications of these editors as well the novel assays in development. They will cover how these and other developments in the field are pushing the envelope of genetic treatments which hopefully will soon be commercially available.
Science and Innovation Concurrent: NOVEL GENOME EDITORS AND THEIR APPLICATION IN HUMAN DISEASE
Chairs:
- Alice Bertaina, MD, PhD, Stanford University, US
Speakers:
- Engineered CRISPR Technologies for Small & Large Genomic Modifications
Benjamin Kleinstiver, PhD, Mass General Hospital & Harvard Medical School, US
- Understanding the safety and genome-wide activity of genome editors for therapeutics
Shengdar Tsai, PhD, St. Jude Children’s Research Hospital, US (Recording and slides not available)
-
Contains 4 Component(s)
Microfluidic systems are introducing unprecedented possibilities to develop miniaturized tissue and organ analogs, as models to investigate features of their development, function and pathology. The session will discuss how the resulting organs-on-chip, beyond their exploitation for drug development and testing, are envisioned to find utilization in the field of cell and gene therapy.
Science and Innovation Concurrent: ORGANS-ON-CHIPS: ADVANCED CULTURE SYSTEMS TO SHAPE FUTURE THERAPIES
Chairs:
- Ivan Martin, PhD, University of Basel, CH
Speakers:
- Beating organs-on-chip as innovative tools for diseases modelling and advanced therapies evaluation: a case
study in cardiac fibrosis
Paola Occhetta, PhD, Politecnico di Milan, IT
- Microfluidic technologies for single cell analysis
Jose Luis Garcia Cordero, PhD, Roche Institute of Human Biology, CH
-
Contains 4 Component(s)
As the demand for advanced therapies continues to grow, improvements in CGT manufacturing workflow are becoming
increasingly necessary. Despite recent advances, the translation of cell and gene therapies to the clinic is still hampered by obstacles that prevent these innovative technologies from becoming standards of care. This session brings together eminent speakers that will provide insights into how to navigate the road to the clinic successfully.
Translation to Clinic Plenary: NEW AVENUES FOR THE CLINICAL TRANSLATION OF CGTS
Chairs:
- Massimiliano Gnecchi, MD, PhD, FESC, University of Pavia & Fondazione IRCCS Policlinico San Matteo, IT
- Miguel Forte, MD, PhD, Kiji Tx/AdBio Partners, BE
Speakers:
- Engineering stem cell environment in vivo through intravital 3D bioprinting (Recordings and slides not available)
Nicola Elvassore, PhD, University of Padova, IT
- A safe way of cloaking cells to evade the immune system
Andras Nagy, PhD, HonD, FRSC, Lunenfeld-Tanenbaum Research Institute, CA
- Repurposed Tumor Cells: A New Approach to Cancer Immunotherapy
Khalid Shah, MS, PhD, Harvard Medical School, US
-
Contains 6 Component(s)
Induced Pluripotent Stem Cell offer unique potential for the development of advanced therapies, however they also have very specific scientific and regulatory challenges. The session will explore quality, preclinical and clinical trials considerations of iPSC master cell banks and products developed from these.
Translation to Clinic Concurrent: ADVANCING IPSCS FOR CLINICAL USE
Chairs:
- Jacqueline Barry, PhD, Cell and Gene Therapy Catapult, UK
Speakers:
- Considerations for the establishment of GMP compliant Master Cell Banks
Tenneille Ludwig, PhD, WiCell Stem Cell Bank
- Developing a Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-
Derived Retinal Pigment Epithelium for Geographic
Atrophy Associated With Age-Related Macular Degeneration.
Kapil Bharti, PhD, National Institutes of Health, US
- iPSC for disease modeling and drug screening
Massimiliano Gnecchi, MD, PhD, FESC, University of Pavia & Fondazione IRCCS Policlinico San Matteo, IT
-
Contains 4 Component(s)
In this session Prof. Antonio Salgado will report about the huge therapeutic potential of MSC-EVs in CNS injury models, Prof. Amanda Silva about a scalable MSC-EV production strategy, and Prof. Eva Rohde about the outcome of an MSC-EV treated cochlear implant patient. Overall the session will provide insights into the different steps of translating MSC-EVs from the bench to the bed side.
Translation to Clinic Concurrent: EXTRACELLULAR VESICLES ARE GETTING HOTTER THAN EVER
Chairs:
- Bernd Giebel, PhD, University Duisburg-Essen, DE
Speakers:
- Clinical translation of extracellular vesicles as a biotherapy: technological challenges and beyond
Amanda Silva, PharmD, PhD, FR
- Stem Cells Secretome as an Emerging Tool for CNS Regeneration
Antonio Salgado, PhD, University of Minho, PT
- First-in-human intracochlear application of human stromal cell-derived extracellular vesicles (Recording and slides not available)
Eva Rohde, MD, Paracelsus Medical University Salzburg, AT
-
Contains 3 Component(s)
To launch the ISCT 2023 Paris Translational Pathway Program, ISCT President Jacques Galipeau is excited to present La Présidentielle, a deep dive into The Future of Immune Effector Cell Therapies for Cancer, featuring Society leaders at the very forefront of the cancer immunotherapy field. This opening session will explore the state of the art in chimeric antigen receptor (CAR) based therapies and other novel technologies for liquid and solid cancers and address persistent and emerging barriers to the successful adoption of these advanced therapies globally.
ISCT 2023 Presidential Plenary: LA PRÉSIDENTIELLE – A DEEP DIVE INTO THE FUTURE OF IMMUNE EFFECTOR CELL THERAPIES FOR CANCER
Chairs:
- Jacques Galipeau, MD, FRCP (C), University of Wisconsin- Madison, US
Speakers:
- Bruce Levine, PhD, University of Pennsylvania, US (Recording not available)
- Anna Sureda, MD, PhD, Institut Català d’Oncologia - Hospital Duran i Reynals (Barcelona), ES (Recording and slides not available)
- Mark Lowdell, PhD, FRCPath, FRSB, InmuneBio Inc., UK
-
Contains 2 Component(s)
Mitochondrial transfer is a relatively new technology mimicking a natural phenomenon through which cells replace the exhausted organelles with new, viable ones obtained from the environment. As pathological conditions are characterized also by mitochondrial dysfunction, the transfer (or transplantation) of new viable mitochondria to damaged cells, tissues or organs has shown promise to become an alternative treatment strategy to restore physiology. This session will present recent progress achieved in the field.
Science and Innovation Concurrent: THE RISE OF MITOCHONDRIAL TRANSFER TECHNOLOGY IN REGENERATIVE MEDICINE
Chairs:
- Rachele Ciccocioppo, MD, AOUI Policlinico GB Rossi & University of Verona, IT
Speakers:
- Mitochondrial Medicine: State of the art and perspective (Recording and slides not available)
Marvin Edeas, MD, PhD, Université de Paris, Institut Cochin, INSERM U1016, FR
- Mitochondrial transfer applications in organ transplantation
Giuseppe Orlando, MD, PhD, Marie Curie Fellow, Wake Forest School of Medicine, US
-
Contains 6 Component(s)
Cell and gene therapies represent a significant achievement, not only for the biotech and life sciences industry but also, and importantly, for patients who have witnessed the lifesaving potential of these new biotherapeutics. The progress for patients could not have been realized without the development of new technologies and this session brings together global experts to discuss the innovations that will shape the future of the field.
Science and Innovation Concurrent: IMPLEMENTING NEW TECHNOLOGIES IN CGT
Chairs:
- Rachele Ciccocioppo, MD, AOUI Policlinico GB Rossi & University of Verona, IT
- Giuseppe Orlando, MD, PhD, Marie Curie Fellow, Wake Forest School of Medicine, US
Speakers:
- The Future of Regulatory T Cell Therapy: Promises and Challenges
Maria Grazia Roncarolo, MD, Stanford University School of Medicine, US
- Bioengineering human organs: Getting to the heart of the matter
Doris Taylor, PhD, FACC, FAHA, Organamet Bio, US
- In vivo engineering of CAR T cells to treat heart disease
Haig Aghajanian, PhD, Capstan Therapeutics, US
-
Contains 6 Component(s)
Nanovesicular therapeutics (NVTs) are expected to have entirely novel properties in targeted drug delivery, providing a promising therapeutic platform for diseases with previously untreatable molecular targets or high unmet clinical need. Various concepts and technologies have been developed, such as the use of externally loaded nanovesicles or naturally secreted extracellular vesicles from unmodified or genetically modified cells from different starting materials. Artificially formed nanovesicular structures generated by serial extrusion techniques from living cells or hybrid constructs derived from a combination of synthetic and biological materials are increasingly being investigated. Few clinical trials have been conducted to date, and proof of efficacy in pivotal studies is still pending, yet expectations are high. This session is devoted to the technological considerations of NVT and the associated therapeutic prospects.
Science and Innovation Concurrent: PROMISE AND OBSTACLES OF CELL-DERIVED NANOVESICULAR THERAPEUTICS
Chairs:
- Eva Rohde, MD, Paracelsus Medical University Salzburg, AT
Speakers:
- Pluripotent stem cells as a source of extracellular vesicles for tissue repair – the other face of iPSCs
Ewa K. Zuba-Surma, PhD, DSc, Jagiellonian University in Krakow, PL
- Extracellular vesicle-based hybrid nanoparticles for therapeutic RNA delivery
Pieter Vader, PhD, University Medical Center Utrecht, NL
- Stromal cell-derived EVs and CDVs: Nanovesicle therapeutics and drug delivery systems
Mario Gimona, PhD, Paracelsus Medical University Salzburg, AT
-
Contains 4 Component(s)
The use of biomaterials has long been envisioned to enhance the therapeutic performance of cellular therapies. The session will highlight opportunities of novel 3D cell culture concepts and technologies towards innovative combined advanced therapy medicinal products.
Science and Innovation Concurrent: SCAFFOLDING AND EXTRACELLULAR MATRIX
Chairs:
- Giuseppe Orlando, MD, PhD, Marie Curie Fellow, Wake Forest School of Medicine, US
Speakers:
- Hurdles in 3D regeneration with multiple cell types (Recording and slides are not available)
Graziella Pellegrini, PhD, Università degli Studi di Modena e Reggio Emilia, IT
- 3D Bioprinting and Light-based Biofabrication in tissue engineering
Riccardo Levato, PhD, Utrecht University, NL
- Cell-based engineering of extracellular matrices designed to activate tissue regeneration
Ivan Martin, PhD, University of Basel, CH
-
Contains 2 Component(s)
This session will focus on discussing approaches to develop novel nucleases, base and prime editors as well as approaches to detect off target activities of the CRISPR/Cas and related nuclease. Speakers will focus on some of the clinical applications of these editors as well the novel assays in development. They will cover how these and other developments in the field are pushing the envelope of genetic treatments which hopefully will soon be commercially available.
Science and Innovation Concurrent: NOVEL GENOME EDITORS AND THEIR APPLICATION IN HUMAN DISEASE
Chairs:
- Alice Bertaina, MD, PhD, Stanford University, US
Speakers:
- Engineered CRISPR Technologies for Small & Large Genomic Modifications
Benjamin Kleinstiver, PhD, Mass General Hospital & Harvard Medical School, US
- Understanding the safety and genome-wide activity of genome editors for therapeutics
Shengdar Tsai, PhD, St. Jude Children’s Research Hospital, US (Recording and slides not available)
-
Contains 4 Component(s)
Microfluidic systems are introducing unprecedented possibilities to develop miniaturized tissue and organ analogs, as models to investigate features of their development, function and pathology. The session will discuss how the resulting organs-on-chip, beyond their exploitation for drug development and testing, are envisioned to find utilization in the field of cell and gene therapy.
Science and Innovation Concurrent: ORGANS-ON-CHIPS: ADVANCED CULTURE SYSTEMS TO SHAPE FUTURE THERAPIES
Chairs:
- Ivan Martin, PhD, University of Basel, CH
Speakers:
- Beating organs-on-chip as innovative tools for diseases modelling and advanced therapies evaluation: a case study in cardiac fibrosis
Paola Occhetta, PhD, Politecnico di Milan, IT
- Microfluidic technologies for single cell analysis
Jose Luis Garcia Cordero, PhD, Roche Institute of Human Biology, CH
-
Contains 4 Component(s)
As the demand for advanced therapies continues to grow, improvements in CGT manufacturing workflow are becoming increasingly necessary. Despite recent advances, the translation of cell and gene therapies to the clinic is still hampered by obstacles that prevent these innovative technologies from becoming standards of care. This session brings together eminent speakers that will provide insights into how to navigate the road to the clinic successfully.
Translation to Clinic Plenary: NEW AVENUES FOR THE CLINICAL TRANSLATION OF CGTS
Chairs:
- Massimiliano Gnecchi, MD, PhD, FESC, University of Pavia & Fondazione IRCCS Policlinico San Matteo, IT
- Miguel Forte, MD, PhD, Kiji Tx/AdBio Partners, BE
Speakers:
- Engineering stem cell environment in vivo through intravital 3D bioprinting (Recordings and slides not available)
Nicola Elvassore, PhD, University of Padova, IT
- A safe way of cloaking cells to evade the immune system
Andras Nagy, PhD, HonD, FRSC, Lunenfeld-Tanenbaum Research Institute, CA
- Repurposed Tumor Cells: A New Approach to Cancer Immunotherapy
Khalid Shah, MS, PhD, Harvard Medical School, US
-
Contains 6 Component(s)
Induced Pluripotent Stem Cell offer unique potential for the development of advanced therapies, however they also have very specific scientific and regulatory challenges. The session will explore quality, preclinical and clinical trials considerations of iPSC master cell banks and products developed from these.
Translation to Clinic Concurrent: ADVANCING IPSCS FOR CLINICAL USE
Chairs:
- Jacqueline Barry, PhD, Cell and Gene Therapy Catapult, UK
Speakers:
- Considerations for the establishment of GMP compliant Master Cell Banks
Tenneille Ludwig, PhD, WiCell Stem Cell Bank
- Developing a Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-
Derived Retinal Pigment Epithelium for Geographic
Atrophy Associated With Age-Related Macular Degeneration.
Kapil Bharti, PhD, National Institutes of Health, US
- iPSC for disease modeling and drug screening
Massimiliano Gnecchi, MD, PhD, FESC, University of Pavia & Fondazione IRCCS Policlinico San Matteo, IT
-
Contains 4 Component(s)
In this session Prof. Antonio Salgado will report about the huge therapeutic potential of MSC-EVs in CNS injury models, Prof. Amanda Silva about a scalable MSC-EV production strategy, and Prof. Eva Rohde about the outcome of an MSC-EV treated cochlear implant patient. Overall the session will provide insights into the different steps of translating MSC-EVs from the bench to the bed side.
Translation to Clinic Concurrent: EXTRACELLULAR VESICLES ARE GETTING HOTTER THAN EVER
Chairs:
- Bernd Giebel, PhD, University Duisburg-Essen, DE
Speakers:
- Clinical translation of extracellular vesicles as a biotherapy: technological challenges and beyond
Amanda Silva, PharmD, PhD, FR
- Stem Cells Secretome as an Emerging Tool for CNS Regeneration
Antonio Salgado, PhD, University of Minho, PT
- First-in-human intracochlear application of human stromal cell-derived extracellular vesicles (Recording and slides not available)
Eva Rohde, MD, Paracelsus Medical University Salzburg, AT
